dTAGV-1 TFA salt form · salt · Parent dTAGV-1 TFA

dTAGV-1 TFA is a selective FKBP12 F36V PORTAC degrader.

For research use only. Not for human or veterinary use.

Target PROTACs FKBP

Research area Cancer

Purity >98% Stock Inquire

Data Sheet SDS COA

dTAGV-1 TFA structure

CAS No.: 2624313-15-9

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
10 mg	USD 498.00	BP-02376A-10mg	In stock	Get quote
25 mg	USD 1,180.00	BP-02376A-25mg	In stock	Get quote
50 mg	USD 1,890.00	BP-02376A-50mg	In stock	Get quote
100 mg	USD 2,900.00	BP-02376A-100mg	In stock	Get quote
250 mg	Inquire	BP-02376A-250mg	In stock	Inquire

Need another size or custom synthesis? Request a quote.

Description

dTAGV-1 TFA is a selective FKBP12 F36V PORTAC degrader. dTAGV-1 TFA induces rapid degradation of FKBP12 F36V-tagged oncogenic fusion proteins, triggering collapse of downstream cellular signaling pathways, reduced proliferative capacity of cancer cells, and decreased levels of target proteins. dTAGV-1 TFA is applicable to functional validation studies of cancer and undegradable oncoproteins .

Biological activity

dTAGV-1 TFA is a potent and selective degrader of mutant FKBP12F36V fusion proteins. dTAGV-1 TFA can induce degradation of FKBP12F36V-Nluc in vivo.

Identifiers

SMILES: OC(C(F)(F)F)=O.O=C([C@H]1N(CCCC1)C([C@H](C2=CC(OC)=C(C(OC)=C2)OC)CC)=O)O[C@@H](C3=C(C=CC=C3)OCC(NCCCCCCC(N[C@@H](C(C)(C)C)C(N4[C@@H](C[C@H](C4)O)C(N[C@H](C5=CC=C(C6=C(C)N=CS6)C=C5)C)=O)=O)=O)=O)CCC7=CC(OC)=C(C=C7)OC
InChIKey: KSEWNBIDXKMTNT-LNVAYBNASA-N

Specifications

MW (average): 1361.5620
Formula: C₇₀H₉₁F₃N₆O₁₆S
CAS No.: 2624313-15-9
Physical state: Solid
Color: White to off-white
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: -20°C, protect from light, stored under nitrogen

Solubility

Soluble in DMSO

In vitro: DMSO : ≥ 100 mg/mL

Documents

References

[1].Nabet B, et al. Rapid and direct control of target protein levels with VHL-recruiting dTAG molecules. Nature communications. 2020 Sep 18;11(1):4687.

[2].Zhu J, et al. FeaSion decodes the regulatory landscape and functional diversity of RNA polymerase II CTD phosphorylation. Science advances. 2025 Nov 28;11(48):eadz2345.

[3].Prindle V, et al. Synthetic lethality of mRNA quality control complexes in cancer. Nature. 2025 Feb;638(8052):1095-1103.

Same target

Search PROTACs

Same research area

Search Cancer